Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
Neuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst Challenges
Q1 2024 Neuronetics Inc Earnings Call Transcript
Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics wins FDA clearance for device to treat adolescents with depression
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.